Clinical trial readout dates for Hemab Therapeutics Holdings Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is July 2027.
| Phase 1/2 HMB-002 (Part A) Von Willebrand Disease (VWD); Von Willebrand Disease (VWD), Type 1 · NCT06754852 | July 2027 Recruiting |
| Phase 1/2 HMB-001 Glanzmann Thrombasthenia · NCT06211634 | August 2027 Ongoing |
| Phase 2 Sutacimig Congenital Factor VII Deficiency · NCT07347249 | November 2027 Recruiting |
| Phase 3 Sutacimig Thrombasthenia · NCT07935356 | November 2029 Recruiting |
Hemab Therapeutics Holdings Inc. reported $430M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-10). Its net loss for that quarter was $27M; at that rate the cash would last about 16 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-11-10 |